News

AMT has concluded two clinical studies for LPLD in Europe and Canada. Long term follow-up from both of these is ongoing, as is a third clinical study in

The company claims that the studies conducted by researchers in the US, including the Centers for Disease Control and Prevention (CDC), showed that antibody-only tests fail to identify

Actavis has launched the product under its own brand name on day one in the UK and France, where the patents expired on 20 and 21 January, respectively.

Originally scheduled for Wednesday, February 24, 2010, the meeting will be rescheduled due to an administrative delay at the FDA. The FDA informed Theratechnologies that the delay is

The FDA requested additional data which the company expects to submit in the third quarter of 2010. The agency did not request any additional efficacy studies. Rajesh Shrotriya,

IsoRay Medical, in conjunction with its Canadian distribution partner, Inter V Medical, looks forward to expand the application of Cesium-131 for other cancer treatment areas of the body.

The company said that the new establishment is an important milestone for its accelerated expansion into global marketplaces. Having explored the Middle East market for five years, Neusoft

The presentations delivered by Robbert de Winter of the Academic Medical Center (AMC) in Amsterdam, and Wojciech Wojakowski from Medical University of Silesia in Poland, focused on the

The company is investing around E30m in planning, developing and constructing the plant, which will produce active ingredients and excipients, products for use in biopharmaceutical production processes, additives